Characteristics of SARSCOV2 infection in vaccinated patients with cancer in one Latin American country: Real world evidence from ACHOCC19-VAC study.

Aylen Vanessa Ospina Serrano ICCAL Hospital Universitario Fundacion Santa Fe de Bogota, Asociacion Colombiana de Hematologia y Oncologia ACHO, Bogotá, Colombia info_outline Aylen Vanessa Ospina Serrano, Ricardo Elias Bruges Maya, Isabel Munevar, Paola Jimenez, William Armando Mantilla, Pedro Ramos, Giovanna Patricia Rivas Tafurt, Mirian Caicedo, Sandra Aruachan, Ana Cristina Avendaño, Ray Manneh Kopp, Ivan Triana, Angela Barrero

Authors Aylen Vanessa Ospina Serrano ICCAL Hospital Universitario Fundacion Santa Fe de Bogota, Asociacion Colombiana de Hematologia y Oncologia ACHO, Bogotá, Colombia info_outline Aylen Vanessa Ospina Serrano, Ricardo Elias Bruges Maya, Isabel Munevar, Paola Jimenez, William Armando Mantilla, Pedro Ramos, Giovanna Patricia Rivas Tafurt, Mirian Caicedo, Sandra Aruachan, Ana Cristina Avendaño, Ray Manneh Kopp, Ivan Triana, Angela Barrero Organizations ICCAL Hospital Universitario Fundacion Santa Fe de Bogota, Asociacion Colombiana de Hematologia y Oncologia ACHO, Bogotá, Colombia, Instituto Nacional de Cancerologia E.S.E., Bogotá, Colombia, Hospital Militar Central, Fundación Cardioinfantil, Hemato Oncólogos Asociados., Bogota, Colombia, Fundación CTIC, Bogota, Colombia, Fundacion Cardio-infantil Instituto de Cardiologia, Bogota, Colombia, Clínica Universitaria Colombia, Sanitas, Oncocare, Bogota, Colombia, Clínica de Occidente, Cali, Colombia, Hemato Oncologos SA, Tuluá, Colombia, IMAT Oncomedica, Monteria, Colombia, Hemato Oncologos SA, Cali, Colombia, Sociedad de Oncología y Hematología del Cesar (SOHEC), Valledupar, Colombia, Fundación Santa Fe de Bogota, Bogotá, Colombia, Asociacion Colombiana de Hematologoia y Oncologia, Bogota, Colombia Abstract Disclosures Research Funding Institutional Funding Asociacion Colombiana de Hematologia y Oncologia ACHO Background: According to results of previous ACHOC-C19 study, mortality in patients with cancer and COVID 19 infection in Colombia is 26%. The impact of vaccination was not evaluated prior to the implementation of this strategy worldwide in patients with cancer. We aimed to characterize SARSCOV 2 infection in a local cohort of vaccinated oncologic patients. Methods: The ACHOCC-19 VAC registry is a national multi-center observational cohort study. Data were collected between April 2021 and March 2022. Inclusion criteria were: age more than 18 years, confirmed diagnosis of cancer (solid tumors), be receiving treatment or being followed-up and have received at least one dose of COVID-19 vaccine. 11 oncologists from 10 health institutions participated. The primary outcome was 30 days mortality due to COVID 19 infection. Secondary outcome was to describe adverse effects related to vaccination. A descriptive univariate and inferential analysis were performed. Results: 720 patients were included, average age was 60 years, 91% lived in urban areas, 12% had low income. 73% (525) were women. The most frequent diagnosis were: breast cancer 47% (338), prostate cancer 7% (50) and lung cancer 4.6% (36). ECOG 0-1 and 2 in 91.7% and 6.1% of population respectively. 41.40% had no comorbidities and 59.4% had 1 or more comorbidity. 29.1% presented metastatic cancer, 59.3% were receiving oncological treatment of which, 32.7% were neoadjuvant or adjuvant and 28.6% palliative. 31.66% were being followed up without treatment. 32.6% had stable disease and 5.9% had cancer in progression. Administered vaccines were CoronaVac (40%), BNT162b2 (35%) others 25%, in accordance with initial availability of vaccines for oncologic population in Colombia. 93.9% of population received 2 doses. COVID19 infection was acquired by 35.9% of the population, 30 days mortality due to infection was 3%. Table 1. Frequency of adverse effects with first and second dose were 14.8% and 12.2%, mild intensity in 93% and 100% respectively, being myalgias (5%), arthralgias (2-3%) and fever (3.5%) the most frequent. Conclusions: In our population, the efficacy of the vaccine against COVID 19 is consistent with available reports in the scientific literature. The incidence of 30 days mortality due to SARCOV 2 infection is very low. Vaccine-related adverse effects had frequency of less than 15% and mild intensity. These findings reinforce the need to promote and intensify vaccination in the oncologic patients. Characteristics of vaccinated patients who died n ( 8) Age median Man 60 years 50% (4) > / = 1 comorbility 75% (6) Prostate cancer Ovarian cancer Lung cancer Colorectal cancer Bladder cancer 37,5% (3) 25% (2) 12.5%( 1) 12.5% (1) 12.5%( 1) TNM IV 75% (6) ECOG 2-3 62,5%(5) Complete vaccination COVID 19 CoronaVac vaccine 100%(8) 62,5%(5) Palliative treatment 62,5%(5) Neoplasm in progression 62,5%(5)